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RESUMO 
Introdução: A síndrome das pernas inquietas (RLS) é um distúrbio sensitivo-motor caracterizado pela 
necessidade incontrolável de mover as pernas. Estudos anteriores revelaram uma resposta significativa 
ao placebo. Objectivo: Quantificar a resposta ao placebo no RLS. Pesquisa: As bases de dados 
MEDLINE, EMBASE, CENTRAL, ICTRP da OMS e Clinicaltrials.gov da FDA foram pesquisados 
em Outubro de 2015. As listas de referências dos estudos incluídos foram analisadas para identificação 
de estudos adicionais. Critérios de selecção: Ensaios aleatorizados com pelo menos um outcome de 
interesse extraível no braço placebo. Colheita e análise de dados: Dois autores extraíram os dados e 
avaliaram o risco de viés de forma independente, sendo os conflitos resolvidos após discussão. A 
medida de efeito escolhida foi o effect size. Foi realizada uma metaanálise dos braços placebo segundo 
o método dos efeitos aleatórios. Resultados: Dos 85 estudos incluídos (5046 participantes), 64 
reportaram avaliações validadas da gravidade, 62 dos quais aplicando a International RLS Study Group 
rating scale (IRLS). O effect size foi -1.41 (95%CI: -1.56; -1.25), correspondendo a -6.58 pontos na 
IRLS. A resposta nocebo (efeitos adversos no braço placebo) foi 45.36%. As respostas placebo e 
nocebo foram superiores em estudos mais longos, ensaios não publicados e com intervenções 
farmacológicas, formas idiopáticas e financiamento pela indústria. O efeito placebo foi menor nos 
outcomes objectivos. Conclusões: A resposta ao placebo no RLS é superior ao limiar de significância 
clínica. A frequência de efeitos adversos teve magnitude considerável. Estes resultados devem ser 
considerados no desenho e interpretação de futuros ensaios clínicos. 
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ABSTRACT 
Background: Restless legs syndrome (RLS) is a common sensorimotor disorder characterized by an 
urge to move the legs. Previous research in the field suggests a substantial placebo response. 
Objective: To quantify the placebo and nocebo responses in RLS. Search methods: The databases 
MEDLINE, EMBASE, CENTRAL, WHO ICTRP and FDA Clinicaltrials.gov, were searched up to 
October 2015. Reference lists were cross-checked for additional studies. Selection criteria: 
Randomized, double-blind, placebo-controlled trials studying RLS were included if quantitative data 
for least one of the outcomes of interest was extractable in the placebo arm. Data collection and 
analysis: Two reviewers independently extracted data and assessed risk of bias. Conflicts were solved 
by discussion. The chosen effect measure was effect size. A random-effects meta-analysis was used to 
pool data from the placebo arms of the included studies. Results: Of the 85 included trials (5046 
participants), 64 reported a validated RLS severity assessment, 62 of which applied the International 
RLS Study Group rating scale (IRLS). The effect size was -1.41 (95%CI: -1.56; -1.25), corresponding 
to -6.58 in IRLS. The nocebo response (adverse events in placebo arm), was 45.36%.  Placebo and 
nocebo responses were greater in trials with longer duration, pharmacological interventions, idiopathic 
RLS, industry funding and in unpublished studies. The placebo response was smaller in objective 
outcomes. Conclusions: The magnitude of the placebo response in RLS is above the threshold for 
clinical significance. The frequency of adverse events was considerable. These results are relevant to 
inform the design and interpretation of future clinical trials. PROSPERO Protocol registration 
number: CRD42015027992. 
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BACKGROUND 
Restless legs syndrome (RLS) or Willis-Ekbom disease is a neurologic disorder characterized by an 
urge to move the legs, usually associated with sensory symptoms1. In 1995, the International RLS 
Study Group (IRLSSG) introduced standardized clinical diagnostic criteria2, which were revised in 
20021. The four essential criteria are: (1) an urge to move the legs, often associated with uncomfortable 
sensations in the legs, with possible additional involvement of the arms or other body parts, (2) 
beginning or worsening during periods of rest or inactivity, (3) being partially or totally relieved by 
movement and (4) only occurring or being worse in the evening or night. 
The importance of RLS relates to its chronic course, impairing both quality of life and sleep in patients 
and their spouses, and to its prevalence, which may reach 10% of the population3.  
The etiology of RLS may be described as idiopathic (primary) or secondary, whose causes include 
iron deficiency anemia4, pregnancy5 and end-stage renal disease6.  
The pathophysiology of RLS is not well understood, though abnormal processes in the central and 
peripheral nervous systems (CNS and PNS, respectively) have been empirically studied. In the CNS 
the main findings relate to two mechanisms: (1) the role of reduced iron stores, found consistently in 
patients with RLS, in the cerebrospinal fluid7 and in the substancia nigra8, suggesting a disruption in 
iron homeostasis and (2) a more contentious role played by a possibly impaired dopaminergic system9. 
In the PNS perhaps the most important finding relates to central sensitization to A-delta fibers 
mechanoreceptor input, showing a static hyperalgesia but a normal dynamic mechanical algesia10. 
In addition to responses to both dopaminergic and opioid agents, several clinical trials in RLS have 
reported considerable improvements under placebo11. Despite the absence of a consensual definition12, 
the placebo response may be defined as “any effect attributable to a pill, potion or procedure, but not 
to its pharmacodynamics or specific properties”13,14.  
In clinical research it is standard practice to use placebo as a comparator for the establishment of the 
true effect of an active intervention14. Additionally, the characterization of the placebo response is an 
important tool in study design, namely in sample size calculations15, and in the interpretation of 
results14.  
A systematic review studying the placebo effect in RLS was performed in 2008, demonstrating a 
considerable symptomatic improvement of participants in the placebo arm of randomized controlled 
trials (RCTs)11. Previous research failed to characterize the nocebo response, i.e., a negative outcome 
resulting from an inert substance or sham procedure16, which will be addressed in the present review. 
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OBJECTIVES 
To quantify the magnitude of placebo and nocebo responses in RLS. 
To identify the determinants of placebo and nocebo responses in RLS. 
To define the sample size required for an adequately-powered trial to detect a difference between 
placebo and any active intervention. 
METHODS 
We followed PRISMA guidelines for the reporting of systematic reviews and meta-analyses17.  
The review protocol was registered with PROSPERO (International prospective register of systematic 
reviews). Protocol registration number: CRD42015027992. 
Inclusion criteria 
Types of studies 
Randomized, double-blind, controlled trials in RLS, regardless of design or setting, with at least one 
active treatment arm and a placebo arm. We excluded trials with an active run-in period before 
intervention with placebo. No language or year of publication limitation was applied. 
Types of participants 
Patients required a diagnosis of RLS according to the International Restless Legs Syndrome Study 
Group (IRLSSG) diagnostic criteria1,2 or another specified method of diagnosis, if the study was 
conducted before the IRLSSG criteria publication. Patients were accepted regardless of RLS etiology, 
comorbid conditions or age. 
Types of interventions 
We accepted any intervention labelled as placebo, sham, dummy or fake. The placebo response data 
were derived from the within-group response in the placebo arm of RCTs.  
Types of outcome measures 
Studies had to report quantitative data on at least one of the following outcomes, measured by validated 
instruments, within the placebo arm:  
 Primary efficacy outcome: “Placebo response”, defined as the within-group change from 
baseline, using any rating scale measuring RLS severity or disability. 
 Primary safety outcome: “Nocebo response”, defined as the proportion of patients experiencing 
all-cause adverse events in the placebo arm. 
 Secondary efficacy outcomes: change from baseline in the following endpoints: 
1. Subjective appraisal of clinical status assessed by physicians with Clinical Global 
Impression - Improvement scale18; 
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2. Subjective appraisal of clinical status assessed by patients with Patient Global Impression 
- Improvement scale; 
3. Quality of life assessments; 
4. Self-rated quality of sleep;  
5. Daytime somnolence; 
6. Sleep efficiency; 
7. Number of periodic limb movements (PLM) per hour of sleep or of time in bed (PLM of 
Sleep Index – PLMSI – and PLM Index – PLMI, respectively). 
 Secondary safety outcomes:  
1. Proportion of patient withdrawals due to adverse events;  
2. Proportion of patients experiencing augmentation, defined as “the worsening of RLS 
symptoms, attributable to a speciﬁc therapeutic intervention for RLS”1. 
Search methods 
We searched the MEDLINE, EMBASE and the Cochrane Register of Controlled Trials (CENTRAL) 
bibliographic databases from inception to October 2015. Clinical trial registries (International Clinical 
Trials Registry Platform of WHO and Clinicaltrials.gov of FDA) were also searched. The developed 
search strategy for all databases combined the terms (placebo OR sham OR dummy) with (Restless 
Legs Syndrome OR RLS OR Ekbom Syndrome OR Periodic Leg Movement OR Periodic Limb 
Movement OR Nocturnal Movement) and was adapted from Cochrane systematic reviews for RLS19,20. 
The Cochrane Highly Sensitive Search Strategy for identifying RCTs on MEDLINE: sensitivity- and 
precision-maximizing version (2008 revision) was used21. The search strategy was restricted to 
humans. All terms were searched as free-text and controlled vocabulary (i.e.: Medical Subjects 
Headings). Reference lists from identified articles were cross-checked in order to detect additional 
eligible studies. Unpublished studies, identified by clinical trials registries searches or through 
references cross-checking, were considered for eligibility as well. 
Data collection and analysis 
Two reviewers (MS and GD) independently screened the titles and abstracts yielded by the search 
against the inclusion criteria and a third reviewer (FR) resolved any disagreements. Two reviewers 
(MS and GD) analyzed full text reports for potential inclusion. We recorded the motives for exclusion 
only at the full-text screening stage. None of the review authors were blinded to the journal titles or to 
the study authors or institutions. 
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Two reviewers (RC and MS) independently extracted individual study data onto a previously piloted 
and tailored Microsoft Excel spreadsheet. 
RLS severity was assessed on the International RLS Study Group rating scale (IRLS), Clinical Global 
Impression – Severity (CGI-S) and by a Visual Analogue Scale (VAS, 0-100). IRLS consists of 10 
items rated by patients from 0 to 4 (with a total score of 0 to 40), with higher values representing 
greater severity22. CGI-S is a domain of CGI scale with scores between “not at all ill” (1) and 
“extremely severe ill” (7)18,23.  
Change in subjective appraisal of clinical status was defined as the percentage of patients rated as 
“much improved” or “very much improved” by physicians in Clinical Global Impression - 
Improvement Scale (CGI-I)18 or by themselves in Patient Global Impression – Improvement Scale 
(PGI-I). 
Quality of life was assessed by the Johns Hopkins Quality of Life questionnaire (RLSQoL)24 and by a 
12-question disease-specific Restless Legs Syndrome Quality of Life questionnaire25. Quality of sleep 
was rated using the following domains of the respective scales: sleep adequacy of the Medical 
Outcomes Study Sleep Scale (MOS)26, satisfaction with sleep of the RLS-6 scale27, overall sleep 
quality of the Post Sleep Questionnaire (PSQ)28, sleep quality of the Pittsburg Sleep Quality Index 
(PSQI)29, quality of sleep of the questionnaire Schlaffragebogen A (SF-A)30, quality of sleep of the 
RLS Quality of Life Instrument (RLS-QLI)31, sleep quality of the Subjective Post-Sleep Diary 
(SPSD)32 and VAS assessments. Daytime somnolence was accessed by MOS (daytime somnolence 
domain), RLS-6 (daytime tiredness item), PSQI (daytime dysfunction domain), IRLS (item 5: tiredness 
or sleepiness) and Epworth Sleepiness Scale (ESS)33.  
Sleep efficiency, PLMSI and PLMI, designated in this review as objective outcomes, were measured 
by polysomnography. Furthermore, we accepted PLMI obtained by actigraphy34 and sleep efficiency 
measured by validated sleep detection devices35.  
Each included study was classified as low, high or unclear risk of bias in the following domains: 
randomization, allocation concealment, blinding of participants and personnel, blinding of outcome 
assessment, incomplete outcome data (according to the following domains: patient and clinician-
reported outcomes and objective measures) and selective reporting, as suggested by the Cochrane 
Collaboration’s tool for assessing risk of bias21. Other sources of bias were also considered, including 
reports on funding, exclusive inclusion of very specific or enriched populations and risk of carry-over 
effect in cross-over trials. Two authors (MS and GD) independently assessed risk of bias after a 
piloting process. Disagreements were solved by consensus or by a third independent party (RF). 
Globally, studies were judged as “low risk” if the risk of bias was considered low in all of the following 
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domains: randomization, allocation concealment and blinding of participants and personnel. 
Reviewers were not blinded to titles, authors or results when performing risk of bias assessment.  
The chosen effect measure for continuous outcomes was effect size (ES) with 95% confidence 
intervals (95%CI). Negative changes indicate improvement in RLS severity, daytime somnolence, 
PLMSI and PLMI, while positive differences illustrate benefit in quality of sleep, quality of life and 
sleep efficiency. The ES was preferably calculated as the quotient of the mean change from baseline 
divided by the standard deviation (SD) of baseline. All effect sizes were corrected for small sample 
bias36. Additionally, we also performed the analyses with the mean change from baseline and SD, 
using the natural units of the most commonly applied scale for each outcome. When a different scale 
was used, linear rescaling to the chosen instrument was conducted37. Finally, in order to facilitate 
sample size definition in future RCTs in the field, we performed sample size calculations to detect 
differences from placebo group of 5, 10, 15 and 20%, according to our results, using R (package pwr). 
In case of insufficient reported data, we contacted trial authors as a first approach. In the lack of a 
positive response, absent mean changes from baseline and SDs were extracted from unpublished 
material. In some trials, SD was obtained from standard error or confidence intervals. When such 
values were not reported, imputation methods were applied as recommended by Cochrane21. When 
articles reported mean, SD of baseline and of final value but not SD of change from baseline, this value 
was calculated according to SDchange =√ SDbaseline
2  + SDendpoint 
2 - (2 r SDbaseline SDendpoint) with r being 
the correlation between baseline and endpoint21. On the other hand, if study reports do not mention SD 
of baseline, an effect size based on SD of change from baseline (ESdiff) was calculated and converted 
into ES, according to ES= ESdiff [2(1-r)] 
1/2 11. In both cases, for each outcome, the correlation between 
baseline and endpoint was computed from other included trials, as recommended by Cochrane21. For 
the primary efficacy outcome, r was estimated for the six largest included studies in which sufficient 
information was reported38-43. The obtained values were confronted with all included studies results 
and the best correlation was selected (r =0.44)42. The smallest40 and largest38 correlations obtained 
were applied and the resulting imputed measurements were used to perform sensitivity analyses. For 
secondary continuous outcomes, the correlation was imputed from the largest included study. The 
estimated correlations were 0.61 for quality of life43; 0.86 for quality of sleep42; 0.92 for daytime 
somnolence42; 0.82 for sleep efficiency; 0.94 for PLMSI44 and 0.43 for PLMI42.    
Heterogeneity statistic (x2) and degree of inconsistency (I2) across studies were calculated using an 
inverse-variance random effect model. 
Publication bias was assessed through visual inspection of funnel plots, concerning the primary 
efficacy outcome. 
Systematic review of the placebo and nocebo responses in Restless Legs Syndrome 
9 
 
We used the Stata Software for data analysis. We pooled data using random-effects, inverse variance 
meta-analysis methods.  
Dichotomous outcomes are reported as percentages with 95%CI and were analyzed with a random 
effects model using the method of DerSimonian and Laird45. Variances were stabilized using Freeman-
Tukey Double Arcsine Transformation46. 
Subgroup analyses were conducted in case of significant heterogeneity. Defined variables for subgroup 
analyses were published versus unpublished trials, study intervention (pharmacological versus non-
pharmacological intervention and mode of administration of pharmacological interventions), study 
population (idiopathic versus secondary RLS as well as naïve versus previously treated patients) and 
time to assessment (less than 6, 6 to 11 weeks and 12 or more weeks). In addition, to assess the 
influence of study quality on the conclusions, subgroup analyses of studies with a low risk of bias 
versus those with unclear or high risk of bias were performed, as well as high risk of bias versus low 
or unclear risk of bias, for each risk of bias domain. 
The subgroup analyses were performed exclusively for the primary outcomes, with the subgroups 
being compared using a fixed effect method. 
For the primary outcomes, sensitivity analyses were conducted excluding studies where imputation 
methods were applied and with cross-over designs. Finally, meta-regressions were performed for the 
primary efficacy outcome according to year of publication and to disease severity at baseline. 
Since our objective was to estimate the placebo response, no formal comparisons were made between 
placebo and active interventions.  
RESULTS 
Description of studies 
See Figure 1 for the study flow diagram. Eighty five RCTs were included in the analysis (5046 
participants). Sixty five trials had a parallel design while 20 were cross-over studies. In 5 included 
studies the active intervention was a non-pharmacological procedure, including direct current 
stimulation (2 studies), magnetic stimulation, infrared light and pneumatic compression. The 
remaining were pharmacological clinical trials, 65 of which with oral interventions. The most common 
studied drugs were ropinirole (13 studies), pramipexole (12 studies), rotigotine (10 studies) and 
gabapentin-enacarbil (10 studies). Five of the included studies were performed exclusively in end-
stage renal disease patients under hemodialysis with secondary RLS. The majority of studies 
exclusively enrolled patients with idiopathic RLS. Overall, the average age was 54.21 years and 
62.24% of patients were female. The mean IRLS score at baseline was 24.51 points. See Table 1 for 
characteristics of included studies. 
Systematic review of the placebo and nocebo responses in Restless Legs Syndrome 
10 
 
Risk of bias assessment showed an adequate random sequence generation in 37 studies, allocation 
concealment in 30 and blinding of participants and personnel in 37. Twenty five studies were 
considered as having a low global risk because all of these three domains were judged as such. One 
study was judged as having a high risk of bias in sequence generation because there was no clear 
mention to randomization. Blinding of outcome assessment was considered satisfactory in all 
outcomes in 33 studies. Risk of bias due to incomplete outcome data was rated as low in 65 trials and 
as high in 12. Thirty seven reports were judged as having a high risk of selective outcome reporting 
and 46 as low risk. All remaining studies were assessed as having an unclear risk of bias in the 
mentioned domains. 
Additional sources of bias were accounted for. Studies were judged as having high risk of other sources 
of bias if they were totally or partially sponsored by a pharmaceutical company (61 studies) and as 
unclear if sources of funding were not reported (8 studies). Studies were also considered as high risk 
if they exclusively included very specific populations, such as, hemodialysis patients (5 studies), or 
enriched population, excluding patients who responded to a placebo run-in phase (4 studies).  In 
addition, cross-over trials were assessed as having an unclear risk of bias if there was no mention made 
on a carryover or sequence effect analysis (8 trials). No other potential source of bias was identified. 
A summary of review authors’ judgements about each domain of the risk of bias analysis is presented 
in Figure 2, while individual studies’ evaluation is provided in Figure 3. 
Effects of interventions 
Primary efficacy outcome: placebo response 
64 studies reported a validated RLS severity assessment that could be included in the primary efficacy 
outcome analyses (4111 patients), 62 of which used the IRLS. Among studies that did not use the 
IRLS, two used severity assessments that were eligible for inclusion: one using CGI-S and the other a 
VAS assessment. Both studies results were rescaled for comparison to IRLS scores. The pooled ES 
was -1.41 (95%CI: -1.56 to -1.25; Figure 4), corresponding to a mean IRLS reduction of 6.58 points 
(95%CI: -8.29 to -4.86). 
Given the substantial heterogeneity (I2=88.1%), we conducted all planned subgroup analyses with the 
exception of naïve versus previously treated patients due to inadequate reporting in the majority of 
studies. None of the subgroup analysis could explain the heterogeneity found (Table 2).  
Subgroup analysis revealed a greater improvement with placebo in studies with 12 or more weeks 
comparing with trials of less than 6 weeks (difference between subgroups (ESdiff): 0.78; 95%CI: 0.59 
to 0.97). Studies with pharmacological interventions reported a larger severity improvement with 
placebo than those with no pharmacological procedures (ESdiff: 0.71; 95%CI: 0.43 to 0.99). RCTs 
performed in idiopathic patients documented larger placebo responses comparing to studies in 
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secondary RLS (ESdiff: 0.76; 95%CI: 0.37 to 1.16). Finally, unpublished trials reported larger 
improvements under placebo, when compared to published manuscripts (ESdiff: 0.42; 95%CI: 0.26 to 
0.59). Subgroup analyses of oral versus non-oral pharmacological interventions did not reveal 
differences between groups. No difference was found between studies with low and high or unclear 
global risk of bias. In terms of the multiple domains of risk of bias assessment, no differences were 
observed, with the exception of funding. Industry-supported studies reported larger placebo responses 
than RCTs with governmental or unspecified funds (ESdiff: 0.60 with 95%CI: 0.43 to 0.77). Subgroup 
analysis of studies that excluded patients who responded to a placebo run-in phase (3 studies, 223 
patients) versus those without such exclusion criteria did not obtain difference on the placebo response. 
No differences were observed in sensitivity analyses (Table 2) nor in meta-regressions regarding both 
disease severity at baseline (Figure 5) and year of publication (Figure 6).  
Primary safety outcome: nocebo response 
The number of patients experiencing adverse events, which was reported in 72 trials, was 2573, out of 
4648 patients. Overall, 45.36% (95%CI: 40.47% to 50.29%) of patients experienced adverse events 
(Figure 7).  
The proportion of patients experiencing any adverse events was greater in studies of 12 or more weeks, 
comparing to studies of less than 6 weeks (difference between subgroups (diff): 32.47%; 95%CI: 
27.49% to 37.45%; Table 2). Pharmacological studies reported superior adverse events rates than trials 
with non-pharmacological interventions (diff: 44.30%; 95%CI: 38.13% to 50.47%), as well as RCTs 
in idiopathic patients, comparing to trials in the secondary form of the disease (diff: 24.69%; 95%CI: 
9.60% to 39.78%). Additionally, unpublished trials documented greater rates of adverse events than 
published studies (diff: 10.66%; 95%CI: 5.09% to 16.23%). 
No difference was observed concerning the global risk of bias. However, when considering the 
financial support of studies, differences were noted. Industry-funded trials reported larger overall 
proportions of participants with adverse events, comparing to studies with other sources of funding 
(diff: 34.42%; 95%CI: 28.74% to 40.10%). 
Secondary efficacy outcomes 
Responses on CGI-I and PGI-I 
17 studies reported both CGI-I and PGI-I, 24 only reported GCI-I and 3 other applied PGI-I, with a 
total of 3749 patients for CGI-I and 1807 for PGI-I. 45.46% of clinical assessments (95%CI: 42.42% 
to 48.52%; I2=68.0%) and 40.00% of patients (95%CI: 34.90% to 45.21%; I2=77.7%) reported a 
response of “much improved” or “very much improved” under placebo. 
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Quality of life 
21 studies reported quality of life assessments in an extractable manner (1919 patients). 14 trials 
applied RLSQoL and 7 used the Restless Legs Syndrome Quality of Life questionnaire. Placebo was 
associated with an improvement in overall quality of life  (ES: 0.67; 95%CI: 0.48 to 0.87; I2=87.7%) 
(Figure 8). 
Daytime somnolence 
31 studies (2138 patients) addressed daytime somnolence, 16 of which applied MOS, 9 ESS, 4 RLS-
6, 1 PSQI and 1 item-5 of IRLS. There was a reduction in daytime somnolence associated with placebo 
(ES: -0.44; 95%CI: -0.61 to -0.27; I2=84.3%). 
Quality of sleep 
Quality of sleep was rated in 35 studies (2555 patients), 17 of those applying MOS, 6 RLS-6, 3 PSQ, 
2 PSQI, 2 SF-A, 2 VAS assessments, 1 RLS-QLI, 1 SPSD and 1 reported MOS, but with a different 
range of scale. A significant improvement was obtained (ES: 0.48; 95%CI: 0.38 to 0.58; I2=63.6%). 
Objective outcomes 
Sleep efficiency, defined as the proportion of total sleep time during time in bed, was reported in 16 
studies (417 participants). All such studies measured total sleep time by polysomnography, with the 
exception of one trial in which a validated sleep detection device (SenseWearTM)35 was used. PLMSI 
was reported in 14 studies (278 patients) and PLMI in 12 studies (553 participants). 4 studies assessed 
PLMI with actigraphy (260 patients). The remaining measurements were performed with 
polysomnography.  
Sleep efficiency revealed an ES of 0.12 (95%CI:-0.01 to 0.26). Regarding PLM, an improvement was 
observed in PLMI (ES: -0.22; 95%CI: -0.35 to -0.12), but not in PLMSI (ES: -0.02; 95%CI: -0.18 to 
0.15).  
Secondary safety outcomes 
Study discontinuation due to adverse events in the placebo arm was reported in 81 studies. A total of 
208 withdrawals, among 4797 participants, was counted, with a proportion of 2.07% patients (95%CI: 
1.39% to 2.85%; I2=38.2%). In 13 patients, among 1863 of 22 studies, augmentation was reported. 
The remaining reports did not address this RLS treatment complication. 
Sample size calculation 
From the primary efficacy outcome, we obtained a 6.58-point reduction on average in IRLS under 
placebo. We calculated the number of participants required for an adequately-powered trial to detect a 
difference between placebo and any active intervention, based on the IRLS (Table 3).  
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DISCUSSION 
This systematic review, which included 85 RCTs (5046 participants), demonstrated a substantial 
placebo response in RLS, with an ES of -1.41, corresponding to a mean reduction in IRLS of 6.58 
points. Due to the high heterogeneity found in our main analysis (I2=88.1%), previously defined 
subgroup analyses were performed. However, they fail to explain the significant heterogeneity (Table 
2).  
Concerning the nocebo response, we documented a high rate of adverse events in the placebo arm 
(45.36%).  
Subgroup analyses revealed placebo and nocebo effects with similar patterns of variation: both 
responses were increased in studies with longer placebo administration, pharmacological 
interventions, idiopathic forms of the disease, industry funding and in unpublished trials. The 
differences found in non-pharmacological studies may be influenced by the fact that most of the studies 
included in this subgroup had a duration inferior to 6 weeks. 
All continuous self-rated outcomes, namely quality of life, quality of sleep and daytime somnolence, 
revealed significant improvements with placebo (Figure 8). Forty percent of patients and 45.5% of 
physicians reported responses of “much/very much improved” under placebo. 
In the objective outcomes, PLM per hour of time in bed revealed a small improvement. The number 
of PLM per hour of sleep remained unchanged, suggesting that placebo might reduce PLM rate only 
when the patient is awake. The magnitude of change under placebo was consistently smaller in 
objective outcomes, comparing to self-rated endpoints (Figure 8). 
Our findings are highly consistent with a previous systematic review11. Substantial placebo responses 
in subjective outcomes, more evident in longer controlled trials, were observed in 2008 and 
corroborated by our findings. The results of the present review were, however, slightly more expressive 
in terms of the improvement in quality of life and quality of sleep. 
In contrast to our results, an analysis of the predictors of placebo response in 6 RCTs in RLS (883 
participants) revealed greater placebo responses in more severe cases and did not obtain differences 
concerning study duration47.  
This review allowed a quantification of the change under placebo in several outcomes in RLS. 
However, two important questions remain: was that change clinically significant? And was it purely 
due to placebo administration? 
For RLS severity, the first question could be answered by the establishment of a minimal clinically 
important difference (MCID) for IRLS. Despite of the absence of a consensual MCID for this scale, 
post hoc analyses of two trials included in this review48,49 obtained a MCID of 550 and 651 points in 
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IRLS. In addition, through the analysis of sample size calculation descriptions in included trials, 15 of 
the 21 studies which reported a minimal significant difference used a value inferior to the pooled 
difference found in our review. The mean of minimal changes across the 21 studies was 5.6 points. 
Hence, it is reasonable to state that the placebo response found in this review reached the threshold for 
clinical significance. 
The answer to the second question has not a clear answer, since we cannot identify in what extension 
were our findings affected by the natural course of the disease. A meta-analysis evaluating both 
placebo and no-treatment control groups in clinical trials, regardless of the condition being studied, 
did not found that placebo interventions have clinically meaningful effects when compared with no 
treatment52.  To the best of our knowledge, such investigation was never performed specifically for 
RLS. Only by the inclusion of both no-treatment and placebo arms in RCTs, will we be able to assess 
if our findings are indeed due to the placebo effect and not related to the natural course of the illness, 
patient-doctor relationship or perhaps to the expectation of being involved in a clinical trial. 
Our exhaustive research of the available evidence, using a sensitive strategy and including online 
clinical trial registries, allowed the inclusion of both published and unpublished RCTs. We can 
therefore assume that there are not many additional eligible studies. Four of the references generated 
by the search could not be retrieved53-56. Even if they corresponded to includable RCTs, those 
references are unlike to report a validated RLS severity assessment, since they were published before 
IRLS validation. Thus, they probably would not have an influence on our primary efficacy outcome. 
Despite of the inclusion of 85 studies, with a total of 5046 participants, there are aspects of interest in 
this review which were generally not reported.  
The vast majority of included RCTs did not report separated results for naïve and previously treated 
patients. An analysis of two large RCTs found that pre-treatment for RLS was associated with a smaller 
placebo response in the placebo arm, in comparison to naïve patients57. The authors postulate that 
previous treatment may contribute to the conscious or unconscious “unblinding” of participants. 
Unfortunately, due to insufficient reporting, we could not perform a subgroup analysis on this matter 
and thus we are not able to corroborate those results.  
Another field lacking sufficient evidence is RLS in children. Only one small trial could be included 
and it had the confound factor of only including Attention Deficit Hyperactivity Disorder patients, 
which is sometimes a misleading diagnosis in RLS children58. Hence, we are not able to draw any 
conclusions concerning RLS in this age group. 
Secondary RLS is also an insufficiently addressed matter, with the vast majority of RCTs excluding 
secondary forms of the disease. Five of the included trials were performed exclusively in end-stage 
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renal disease patients under hemodialysis. Those were mostly small trials (total of 62 patients, 32 of 
which being evaluated for our primary efficacy outcome). Hence, due to the small number of uremic 
RLS patients, our conclusions on this matter should be regarded with caution.  No trials in pregnant 
women with RLS nor exclusively in patients with iron deficient anemia were detected by our research. 
Therefore, it is reasonable to state that there is a considerable lack of evidence concerning secondary 
RLS.          
Finally, it is important to notice that less than half of the included studies reported augmentation (22 
RCTs, 1846 patients).  Typically augmentation is regarded as a complication of long-term treatment, 
however, it may occur at any time, including the first week of pharmacological intervention1. Thus, 
the absence of report on this outcome, including in 14 RCTs with a duration of 12 or more weeks, may 
be regarded as a diminishing factor of the quality of the included body of evidence. 
Regarding the methodological quality of included studies, there was an incomplete description of study 
procedures in a considerable number of studies, with only 25 RCTs being judged as low risk of bias 
simultaneously in sequence generation, allocation concealment and blinding of participants and 
personnel. Additionally, 38 trials were considered as having high risks of bias in incomplete outcome 
data and/or selective reporting, mainly because of the absence of report on reasons for study 
discontinuation and incomplete data description, precluding the inclusion of one or more outcomes in 
the analysis.  
Efforts were made to prevent bias resulting of our search process, namely by the inclusion of 
unpublished material and all eligible RCTs regardless of their publication language. However, despite 
of contacting authors for missing data, we did not request some information that could have been 
useful, such as, separated results for naïve/previously treated patients and methodologic aspects 
whenever they were judged as having unclear risks of bias. Moreover, we only extracted results of 
final evaluations of each trial, even if more than one time point during the study was reported. Another 
limitation of our review, which could be further explored in future work, is the absence of an analysis 
of which adverse effects occurred under placebo. Despite of our focus in the nocebo response, we only 
accounted for global adverse events rates, regardless of their nature and of being attributed to the study 
intervention or not. 
In terms of the meta-analysis itself, we performed a sensitivity analysis for every process that could 
be, in our regard, a source of bias. The exclusion of every study where imputation methods were 
applied revealed no difference in the results. Sensitivity analysis were performed exclusively for the 
primary efficacy outcome. Thus, we are not certain of the influence of imputation methods in other 
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outcomes, particularly in quality of life, quality of sleep and daytime somnolence, in whose these 
methods were frequently applied. 
AUTHORS’ CONCLUSIONS 
The magnitude of the placebo response in RLS is substantial, reaching the threshold for clinical 
significance. The nocebo response is likewise considerable. Placebo and nocebo responses show 
similar patterns of variation, both being increased in longer RCTs, studies with pharmacological 
interventions, trials in idiopathic RLS, industry-sponsored studies and unpublished trials. The 
improvement under placebo is substantially smaller in objective outcomes. 
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 Wrong intervention (n = 1) 
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(meta-analysis)  
(n = 85) 
Figure 1: Study flow diagram.  
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Figure 2: Risk of bias graph: each methodological quality item is presented as percentages across 
included studies. 
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Table 1: Included studies description.  
Study Design 
Active Intervention 
(administration method) 
Assessment 
Week 
Extractable 
Outcomes 
Placebo Group 
n Age F (%) 
Naïve 
(%) 
Sec. 
(%) 
Parallel-group:         
Koo et al. (2015)59  
Direct current stimulation 
(tc) 
≈3 S, C, P, W, AE 11 46 100 100 0 
Zhang et al. (2015)60  Pramipexole (o) 12 S, C, W, AE 102 52,9 62 nd 0 
Allen et al. (2014)38  
Pramipexole; pregabalin 
(o) 
12 S, C, Qs, Ql, Ag 173 53,5 62 nd 0 
Altunrende et al. (2014)61  Magnetic stimulation (tc) ≈4 S, W, AE, Ag 8 58,1 25 0 0 
Sica et al. (2014)62 
Rotigotine (td) 4 
S, C, Qs, DS, Ql, PI, 
W, AE 
40 56 29 nd 0 
GlaxoSmithKline (2014)63  Gabapentin enacarbil (o) 12 S, C, W, AE 121 52,1 55 nd 0 
UCB Pharma (2014)64 Rotigotine (td) 7 S, Qs, DS, W, AE 49 47,9 41 nd 0 
Otsuka Pharmaceutical 
(2014)65  
Rotigotine (td) 6 S, P, W, AE 58 48,6 65 nd 0 
Winkelman et al. (2014)66  Rotigotine (td) 5 
S, Qs, DS, Ql, SE, PI, 
W, AE 
10 50,7 30 nd 100 
Trenkwalder et al. (2013)67  Oxycodone+naloxone (o) 12 S, C, Qs, W, AE, Ag 154 61,7 68 23 0 
Inoue et al. (2013a)68  Rotigotine (td) 13 S, C, P, W, AE 95 53,4 57 92 0 
Giannaki et al. (2013)69  Ropinirole (o) 26 S, DS, W, AE, Ag 7 56,8 29 100 100 
Giorgi et al. (2013)70,71 Ropinirole (o) 26 
S, C, Qs, DS, Ql, W, 
AE, Ag 
207 56,1 63 nd 0 
Inoue et al. (2013b)72  Gabapentin enacarbil (o) 12 S, C, P, W, AE, Ag 116 52,1 47 86 0 
Lal et al. (2012)73,74 Gabapentin enacarbil (o) 12 
S, C, P, Qs, W, AE, 
Ag 
41 47,1 71 nd 0 
Sagheb et al. (2012)75  Vitamin C and E (o) 8 S, W, AE 15 59,5 40 nd 100 
Ma et al. (2012)76  Pramipexole (o) 6 
S, C, P, Qs, DS, W, 
AE 
103 56,9 73 nd 0 
Weinstock et al. (2012)77  Rifaximin (o) ≈3 S, W, AE 9 60 80 nd 0 
Bayard et al. (2011)78  Bupropion (o) 6 S, W 31 50,5 77 nd 0 
Lee et al. (2011)79  Gabapentin enacarbil (o) 12 S, C, P, Qs, DS, Ql 96 49,1 59 61 0 
England et al. (2011)80  C-dopa+l-dopa (o) 8-13 S 4 9,6 38 nd nd 
Manconi et al. (2011)81  Pramipexole (o) 0c SE, PS, W, AE 15 58,1 67 100 0 
Högl et al. (2011)82  Pramipexole (o) 26 S, C, P, W, AE, Ag 163 55,8 58 76 0 
Benes et al. (2011)83  Ropinirole (o) 12 S, C, W, AE 67 59,5 67 nd 0 
Montagna et al. (2011)41  Pramipexole (o) 12 S, C, P, W, AE 200 56,1 73 nd 0 
Allen et al. (2011)84  Ferric carboxymaltose (iv) 4 S, C, P, Ql, W, AE 21 54,8 53 26 0 
GlaxoSmithKline (2011)85  Gabapentin enacarbil (o) 2 DS, W, AE 34 49,6 59 nd 0 
Mitchell et al. (2011)86  Infrared light (tct) 4 S, W 17 55,5 47 nd nd 
Oertel et al. (2010)87  Rotigotine (td) 7 
S, C, Qs, DS, Ql, SE, 
PS, PI, W, AE 
21 56,3 70 55 0 
Hening et al. (2010)48  Rotigotine (td) 29 
S, C, Qs, DS, Ql, W, 
AE, Ag 
100 52,8 57 nd 0 
Allen et al.(2010)88  Pregabalin (o) 6 
S, C, Qs, DS, Ql, SE, 
W, AE 
23 50,3 57 nd 0 
Garcia-Borreguero et al. 
(2010)44  
Pregabalin (o) 12 
S, Qs,DS, SE, PS, W, 
AE, Ag 
28 53 nd 89 0 
Inoue et al. (2010)89  Pramipexole (o) 6 S, P, Qs, DS, W, AE 21 62,3 48 nd 0 
Walters et al. (2009)90  Gabapentin enacarbil (o) 2 S, C, Qs, W, AE 33 49,4 52 100 0 
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Grote et al. (2009)91  Iron sucrose (iv) 3 S 31 46 90 nd 0 
Cuellar et al. (2009)92  Valerian (o) 8 S, Qs, DS, W 20 48,7 75 nd nd 
Wang et al. (2009)93  Ferrous sulfate (o) 12 S, W 7 58 71 nd 0 
Kushida et al. (2009a)94  Gabapentin enacarbil (o) 12 
S, C, P, Qs, DS, Ql, 
W, AE 
108 50,2 60 65 0 
Jama et al. (2009)95  Pramipexole (o) 3 S, C, P, DS, W, AE 22 53,3 81 67 0 
Lettieri et al. (2009)96  
Pneumatic compression 
(lw) 
4 S, Qs, DS, W, AE 14 47,8 50 nd nd 
Earley et al. (2009)97  Iron sucrose (iv) 2 S, PS, W, AE 7 61,4 71 nd 0 
Ferini-Strambi et al. 
(2008)39  
Pramipexole (o) 12 S, C, P, W, AE 187 56,3 64 70 0 
Kushida et al. (2008)40  Ropinirole (o) 12 
S, C, P, Qs, DS, Ql, 
PIb, W, AE 
186 50,4 58 nd 0 
Trenkwalder et al. (2008)49  Rotigotine (td) 29 
S, C, Qs, DS, Ql, W, 
AE, Ag 
117 59,7 70 25 0 
Boehringer Ingelheim 
(2008)98  
Pramipexole (o) 6 W, AE 132 nd nd nd 0 
GlaxoSmithKline (2008a)43  Ropinirole (o) 12 
S, C, Qs, DS, Ql, W, 
AE 
195 52,3 68 nd 0 
GlaxoSmithKline (2008b)99  Ropinirole (o) 12 
S, C, Qs, DS, SE, PI, 
W, AE 
19 49,8 89 nd 0 
Oertel et al. (2008)100  Rotigotine (td) 6 
S, C, Qs, DS, Ql, W, 
AE 
55 58,5 60 23 0 
Garcia-Borreguero et al. 
(2007)101  
Sumanirole (o) 8 S, C, PS, W, AE 51 52,9 58 nd 0 
Oertel et al. (2007)102  Pramipexole (o) 6 S, C, P, DS, W, AE 115 55,8 68 68 0 
Oertel et al. (2006)103  Cabergoline (o) 5 
S, C, Qs, DS, Ql, SE, 
PS, PI, W, AE, Ag 
20 55,5 75 20 0 
Winkelman et al. (2006)104  Pramipexole (o) 12 
S, C, P, DS, Ql, W, 
AE 
86 51,5 64 81 0 
Bogan et al. (2006)42  Ropinirole (o) 12d 
S, C, Qs, DS, Ql, PIb, 
W, AE, Ag 
193 52,4 64 nd 0 
GlaxoSmithKline (2006)105  Ropinirole (o) 12 
C,  P, Qs, DS, Ql, PIb, 
W, AE 
149 56,8 75 nd 0 
GlaxoSmithKline (2005)106  Ropinirole (o) 7 S, W, AE 17 56,2 76 nd nd 
tiasny-Kolster et al. 
(2004a)107  
Cabergoline (o) 5 S, Qs, W, AE, Ag 22 55,6 82 36 0 
Allen et al. (2004)108,109 Ropinirole (o) 12 
S, C, Qs, DS, Ql, SE, 
PS, W, AE, Ag 
33 53,2 57 50 0 
Stiasny-Kolster et al. 
(2004b)110  
Rotigotine (td) 1 S, C, DS, W, AE 14 60,1 50 14 0 
Walters et al. (2004)111  Ropinirole (o) 12 
S, C, Qs, DS, Ql, W, 
AE, Ag 
136 56 61 nd 0 
Trenkwalder et al. 
(2004a)112  
Pergolide (o) 6 
S,  P, SE, PI, W, AE, 
Ag 
53 58,1 53 47 0 
Sloand et al. (2004)113  Iron dextran (iv) 4 W, AE 14 54,4 29 nd 100 
Trenkwalder et al. 
(2004b)114  
Ropinirole (o) 12 
S, C, Qs, DS, Ql, W, 
AE, Ag 
138 56,2 66 nd 0 
Davis et al. (2000)115  Ferrous sulfate (o) 12 Qs, W, AE 14 59,9 71 0 nd 
Earley et al. (1998)116  Pergolide (o) ≈3 W, Ag 8 56,5 38 50 nd 
Telstad et al. (1984)117  Carbamazepine (o) 5 W, AE 90 52d 72 nd 0 
Cross-over:         
Garcia-Borreguero et al. 
(2014)118  
Pregabalin, pramipexole (o) 4a C, W, AE 73 54,3 64 nd 0 
Heide et al. (2014)119  
Spinal direct current 
stimulation (tct)  
0a c S, W, AE 20 56,2 75 10 0 
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Rahimdel et al. (2012)120  Selenium (o) 4a S 60 51,8 57 nd 0 
Winkelman et al. (2011)121  Gabapentin enacarbil (o) 4a 
S, C, Qs, SE, PI, W, 
AE 
132 52 58 58 0 
Kushida et al. (2009b)122  Gabapentin enacarbil (o) 2a 
S, C,  P, Qs, SE, PS, 
PI, W, AE 
36 50,1 58 100 0 
Nahab et al. (2008)123  Botulinum toxin A (im) 4a S, W, AE 6 57,7 50 0 0 
Polo et al. (2007)124  
L-dopa+c-
dopa±entacapone (o) 
0a c PS, W, AE 28 51,2 64 100 0 
Eisensehr et al. (2004)125  Valproic acid; l-dopa (o) 3a SE, PS, W, AE, Ag 20 58,9 60 nd 0 
Adler et al. (2004)126  Ropinirole (o) 4a S, DS, W, AE 22 60 73 59 0 
Saletu et al. (2003)127  L-dopa (o) 0a c W, AE 21 63 62 nd 0 
Garcia-Borreguero et al. 
(2002)128  
Gababentin (o) 6a W, AE, Ag 24 55 67 nd 8 
Thorp et al. (2001)129  Gabapentin enacarbil (o) 6a W 16 64 6 nd 100 
Benes et al. (1999)130  L-dopa+benserazide (o) 4a Qs, PIb, W, AE 32 56 59 50 12 
Wetter et al. (1999)131  Pergolide (o) 4a S, Qs, W 29 57,2 53 33 0 
Montplaisir et al. (1999)132  Pramipexole (o) 4a SE, PS, W 10 49,3 44 20 0 
Wagner et al. (1996)133  Clonidine (o) 2-3a SE, PS, W, AE 10 44,5 27 nd 0 
Trenkwalder et al. 
(1995)134  
L-dopa (o) 4a AE 32 52 36 nd 39 
Walters et al. (1993)135  Oxycodone (o) 2a SE, PS, W 11 55,3 45 nd 0 
Walters et al. (1988)136  Bromocriptine (o) 4a SE, PS 6 61 33 nd 0 
Boghen et al. (1986)137  Clonazepam (o) 4a W, AE 6 45,8 50 nd 0 
n: number of patients; F(%): percentage of women; Sec: secondary restless legs syndrome; l-dopa: levodopa; c-dopa: 
carbidopa; tc: transcranial; o: oral; td: transdermal; iv: intravenous; tct: transcutaneous; lw: leg wraps;  im: intramuscular; 
S: severity; C: Clinical Global Impression – Improvement; P: Patient Global Impression – Improvement; Qs: quality of 
sleep; DS: daytime somnolence; Ql: quality of life; SE: sleep efficiency; PS: periodic limb movements of sleep index; 
PI: periodic limb movements index; W: proportion of patient withdrawals due to adverse events; AE: proportion of 
patients experiencing adverse events; Ag: proportion of patients experiencing augmentation; aduration of each treatment 
period, bmeasured by actigraphy, csingle dose with assessment in the same day, dweek assessment for PLMI: 6; dmedian; 
nd: not described. 
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Figure 3: Risk of bias summary. 
*”Blinding of participants and personnel” was judged as low risk for objective outcomes and as unclear risk for other outcomes. 
**”Incomplete outcome data” was judged as high risk for IRLS and as low risk for other outcomes. 
***”Incomplete outcome data” was judged as unclear for PLMSI and as low risk for other outcomes. 
Blank spaces were left whenever an item was not applicable. 
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Figure 4: Change from baseline in RLS severity under placebo. Effect size with 95%CI. 
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Table 2: Subgroup analyses for the primary outcomes.  
  Placebo Response Nocebo Response 
  RLS Severity Adverse Events 
  Effect size (95%CI) I2 (%) % (95%CI) I
2 (%) 
Global Results     
 -1.41 (-1.56 to -1.25) 88.1 45.36 ( 40.47 to 50.29) 89.8 
Subgroup Analysis    
 
Study Duration (weeks)     
 < 6 -1.01 (-1.33 to -0.70) 81.3 28.35 (20.92 to 36.35) 80.7 
 [6 - 12[ -1.18 (-1.43 to -0.93) 72.2 49.00 (41.61 to 56.42) 76.9 
 ≥ 12 -1.79 (-1.98 to -1.60) 89.1 60.82 (54.96 to 66.53) 89.6 
Intervention    
 
 Non-pharmacological -0.75 (-1.26 to -0.23) 52.4 3.58 (0.00 to 21.90) 70.9 
 Pharmacological -1.45 (-1.61 to -1.30) 88.3 47.88 (43.14 to 52.64) 88.9 
      Oral -1.43 (-1.62 to -1.24) 90.4 47.85 (42.48 to 53.23) 90.1 
      Non-oral -1.53 (-1.78 to -1.28) 66.5 47.93 (37.75 to 58.20) 81.8 
Etiology    
 
 Idiopathic -1.48 (-1.64 to -1.32) 88.8 48.91 (44.06 to 53.78) 89.2 
 Secondary -0.72 (-1.46 to 0.03) 49.7 24.22 (1.27 to 58.58) 80.5 
Publication Status    
 
 Published -1.36 (-1.53 to -1.19) 88.8 43.70 (38.19 to 49.28) 90.4 
 Unpublished -1.78 (-2.06 to -1.51) 57.9 54.36 (45.01 to 63.57) 82.9 
Global Risk of Bias*    
 
 Low -1.46 (-1.72 to -1.19) 90.1 46.13 (37.75 to 54.61) 90.8 
 Unclear or High -1.38 (-1.57 to -1.19) 87 44.93 (38.85 to 51.08) 89.4 
      
Sensitivity Analysis     
 Excluding cross-over trials -1.51 (-1.66 to -1.36) 86.3 51.21 (46.34 to 56.07) 88.3 
 Excluding imputed results -1.59 (-1.745 to -1.43) 85.3 -  
Subgroup analyses for RLS severity were conducted using a random effects model, with the comparison between 
subgroups being performed with a fixed effect method.   
*Studies were judged as “low risk” if the risk of bias was considered low in all of the following domains: 
randomization, allocation concealment and blinding of participants and personnel. 
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Figure 5: Meta-regression of disease severity at baseline, based on IRLS score. 
Figure 6: Meta-regression according to year of publication. 
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  Figure 7: Adverse events rate under placebo. Proportion with 95%CI. 
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Figure 8: Change from baseline under placebo in secondary efficacy outcomes. Effect size with 95%CI. 
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Table 3:  Sample sizes required to detect differences from placebo in ILRS. 
Difference from placebo in IRLS (points) n 
 2 180 
 4 45 
 6 20 
 8 12 
 10 8 
n: number of participants allocated to each arm, in a 1:1 randomized trial. 
